Neuroprosthetics

Newronika Announces First Patient Implanted with AlphaDBSTM Closed-loop Adaptive Deep Brain Stimulation System

Retrieved on: 
Thursday, February 4, 2021
Branches of biology, Medicine, Clinical medicine, Neurotechnology, Neuroprosthetics, Electrotherapy, Medical devices, Deep brain stimulation, Tourette syndrome, Parkinson's disease, Neuromodulation, Parkinson's disease clinical research

Newronika has initiated a multi-center clinical trial to evaluate the AlphaDBS adaptive closed-loop system in patients with Parkinson's disease.

Key Points: 
  • Newronika has initiated a multi-center clinical trial to evaluate the AlphaDBS adaptive closed-loop system in patients with Parkinson's disease.
  • The neuronal activity recorded in the first patient with Parkinson's disease from the fully implanted system confirms the intended performance of the AlphaDBS System.
  • The data collected using the implanted system corroborate previous findings from studies of 48 patients using an external system in three different investigational clinical trials.
  • AlphaDBS is a unique deep brain stimulation system that continuously records and interprets bioelectrical neuronal activity in the brain where stimulation is delivered.

GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primates

Retrieved on: 
Thursday, February 4, 2021
Biotechnology, Pharmaceutical, Optical, Health, Branches of biology, Biology, G protein-coupled receptors, Neuroprosthetics, Opsin, Vision, Neurological disorders, Optogenetics, Photophobia, GenSight Biologics, GS030, Optogenetics, Retinitis Pigmentosa (RP)

Optogenetics combine the cellular expression of light-sensitive opsins with fine-tuned light stimulation generated by a wearable optronic visual stimulation device (GS030-MD).

Key Points: 
  • Optogenetics combine the cellular expression of light-sensitive opsins with fine-tuned light stimulation generated by a wearable optronic visual stimulation device (GS030-MD).
  • This preclinical study represents an important milestone towards the clinical validation of this approach to restore some vision in blinding retinal conditions.
  • We expect that the results of the clinical trial PIONEER will indeed confirm the potency of the approach in the interest of patients.
  • Under ambient lighting, no photophobia or visionrelated changes in behavior was noted in any of the animals injected with rAAV2.7m8-ChrimsonR-tdT.

Nanoscope® team conferred Phase II Retinal Organoid Challenge (ROC) award by National Institute of Health

Retrieved on: 
Tuesday, February 2, 2021
Branches of biology, Biology, Vision, Emerging technologies, G protein-coupled receptors, Stem cells, Neuroprosthetics, Organoid, Stargardt disease, Optogenetics, Opsin, Retina

BEDFORD,Texas, Feb. 2, 2021 /PRNewswire/ --To meet the advance challenge for generating a physiologically relevant three-dimensional (3D) retinal organoid, Nanoscope researchers in collaboration withUniversity of Colorado, and Miami Universitywere recently awarded the top prize from the 3D-ROC challenge by the National Institute of Health (NIH).

Key Points: 
  • BEDFORD,Texas, Feb. 2, 2021 /PRNewswire/ --To meet the advance challenge for generating a physiologically relevant three-dimensional (3D) retinal organoid, Nanoscope researchers in collaboration withUniversity of Colorado, and Miami Universitywere recently awarded the top prize from the 3D-ROC challenge by the National Institute of Health (NIH).
  • https://www.nei.nih.gov/about/goals-and-accomplishments/nei-research-ini...
    The organoids provide a unique opportunity for evaluating novel gene therapies including Multi-Characteristic Opsin (MCO) gene therapy for vision restoration.
  • This is an active therapeutic development area for Nanoscope Therapeutics to evaluate effectiveness of MCO optogenetic therapy, which has shown promise in restoring sight in blind subjects.
  • Our pipeline includes optogenetics based retinal regeneration therapy for vision restoration in patients with RP, Stargardt disease, and dry-AMD.

Global Cardiac Pacemakers Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, February 1, 2021
Health, Medical devices, Cardiology, Cardiac electrophysiology, Medical technology, Branches of biology, Embedded systems, Medical devices, Neuroprosthetics, Science and technology, Cybernetics, Artificial cardiac pacemaker, Heart

The implantable cardiac pacemakers captured the largest market share, and it is expected to grow with a lucrative growth rate, over the forecast period.

Key Points: 
  • The implantable cardiac pacemakers captured the largest market share, and it is expected to grow with a lucrative growth rate, over the forecast period.
  • The implantable pacemakers are of three major types, namely single chamber, dual chamber, and biventricular pacemakers.
  • Biventricular pacemakers are expected to gain momentum, owing to the presence of multiple leads.
  • Therefore, implantable cardiac pacemakers are expected to show a significant growth, during the forecast period.

Can Brain Implants Improve Mobility After Stroke?

Retrieved on: 
Monday, February 1, 2021
Branches of biology, Biomedical engineering, Neuroprosthetics, Neuroscience, Neural engineering, Brain–computer interfacing, Emerging technologies, Prosthetics, Brain implant, Implant, Brain, Human brain

When it happens, blood clots or bleeds kill a part of the brain it goes dark and can no longer control part of the body.

Key Points: 
  • When it happens, blood clots or bleeds kill a part of the brain it goes dark and can no longer control part of the body.
  • "This study serves as a proof of concept, a necessary bridge to future studies that would use fully implanted wireless electrodes to improve movement after stroke."
  • In those patients, electrodes that recorded brain signals were implanted in the brain tissue and connected by wires extending through the skull to a computer.
  • But those abilities were only available to the patients as long as the brain implants were in place.

Global Defibrillator Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, January 29, 2021
Health, Medical devices, Cardiology, Cardiac electrophysiology, Branches of biology, Medical technology, Medical devices, Medicine, Neuroprosthetics, Biomedical engineering, Prosthetics, Implantable cardioverter-defibrillator, Artificial cardiac pacemaker, Cardiac resynchronization therapy, Cardiomyopathy

The implantable cardioverter defibrillator (ICD) segment accounted for the largest share in the global market.

Key Points: 
  • The implantable cardioverter defibrillator (ICD) segment accounted for the largest share in the global market.
  • The ICDs are of three major types, namely transvenous ICDs, subcutaneous ICDs, and CRT with pacemaker and ICD function.
  • Moreover, according to the Australian Institute of Health and Welfare, in 2017, approximately 4,578 people died, due to heart failure and cardiomyopathy.
  • The increasing prevalence of cardiovascular diseases in the region is expected to drive the market growth, over the forecast period.

Vagus Nerve Stimulator Market Expected To Rise At A CAGR Of 12.8% By 2026, Estimates DelveInsight

Retrieved on: 
Wednesday, January 20, 2021
Branches of biology, Neuroscience, Neurotechnology, Neuroprosthetics, Electrotherapy, Surgery, Vagus nerve stimulation, Stimulator, Neurophysiology, Vagus nerve, The Stimulators, Implant

LAS VEGAS, Jan. 20, 2021 /PRNewswire/ -- DelveInsight's Vagus Nerve Stimulator Market reportprovides the current and forecast market of the Vagus nerve stimulator devices and comprises of market trends and key competitors of Vagus nerve stimulator devices.

Key Points: 
  • LAS VEGAS, Jan. 20, 2021 /PRNewswire/ -- DelveInsight's Vagus Nerve Stimulator Market reportprovides the current and forecast market of the Vagus nerve stimulator devices and comprises of market trends and key competitors of Vagus nerve stimulator devices.
  • Key Highlights from DelveInsight's Vagus Nerve Stimulator Market report:
    According to the estimates, the highest contribution in the market size of Vagus Nerve Stimulator (VNS) is from the United States (89.06%), followed by Japan among the seven major markets.
  • Vagus nerve stimulators are used for stimulation of the vagus nerve by the help of electrical impulses.
  • A Vagus Nerve Stimulator that can be implanted has been approved by the FDA for both epilepsy and depression.

Vagus Nerve Stimulator Market Expected To Rise At A CAGR Of 12.8% By 2026, Estimates DelveInsight

Retrieved on: 
Wednesday, January 20, 2021
Branches of biology, Neuroscience, Medicine, Neurotechnology, Neuroprosthetics, Electrotherapy, Surgery, Vagus nerve stimulation, Stimulator, Vagus nerve, Neuromodulation, The Stimulators

The decent growth in the Vagus Nerve Stimulator Market size can be attributed to an increasing incidence rate of neurological conditions, the resistance of patients to epileptic or anti-depressants drugs, and increasing demand for innovative devices

Key Points: 
  • The decent growth in the Vagus Nerve Stimulator Market size can be attributed to an increasing incidence rate of neurological conditions, the resistance of patients to epileptic or anti-depressants drugs, and increasing demand for innovative devices
    LAS VEGAS, Jan. 20, 2021 /PRNewswire/ -- DelveInsight's Vagus Nerve Stimulator Market reportprovides the current and forecast market of the Vagus nerve stimulator devices and comprises of market trends and key competitors of Vagus nerve stimulator devices.
  • Key Highlights from DelveInsight's Vagus Nerve Stimulator Market report:
    According to the estimates, the highest contribution in the market size of Vagus Nerve Stimulator (VNS) is from the United States (89.06%), followed by Japan among the seven major markets.
  • Vagus nerve stimulators are used for stimulation of the vagus nerve by the help of electrical impulses.
  • A Vagus Nerve Stimulator that can be implanted has been approved by the FDA for both epilepsy and depression.

Sensorion Announces Preclinical Data Demonstrating SENS-401’s Potential to Preserve Residual Hearing After Cochlear Implantation

Retrieved on: 
Tuesday, January 19, 2021
Biotechnology, General Health, Medical devices, Health, Clinical trials, Audiology, Otology, Otorhinolaryngology, Branches of biology, Health sciences, Artificial organs, Bionics, Neuroprosthetics, Cochlear implant, Cochlear, Hearing loss, Implant

But preserving acoustic hearing in patients with less severe forms of hearing loss who receive cochlear implants could provide a substantial benefit to this population, said Nawal Ouzren, CEO of Sensorion.

Key Points: 
  • But preserving acoustic hearing in patients with less severe forms of hearing loss who receive cochlear implants could provide a substantial benefit to this population, said Nawal Ouzren, CEO of Sensorion.
  • The preclinical program was conducted as part of a collaboration between Sensorion and Cochlear (ASX: COH), the global leader in implantable hearing solutions.
  • The study was designed to determine whether SENS-401 has the potential to improve preservation of residual acoustic hearing after cochlear implantation.
  • Either SENS-401 or a placebo was delivered via an eluting electrode in an established pre-clinical model of cochlear implantation.

Mended Hearts' Pace of Mind Campaign Educates Patients Diagnosed With Heart Conditions About New Pacing Options

Retrieved on: 
Tuesday, January 12, 2021
Medical technology, Branches of biology, Cardiac electrophysiology, Medicine, Embedded systems, Prosthetics, Medical devices, Neuroprosthetics, Mended Hearts, Artificial cardiac pacemaker, Pacing, Pacemaker

Pace of Mind ( PaceOfMind.org ) shares the personal stories of adults living with leadless pacemakers and includes resources to help educate patients about their potential pacing options.

Key Points: 
  • Pace of Mind ( PaceOfMind.org ) shares the personal stories of adults living with leadless pacemakers and includes resources to help educate patients about their potential pacing options.
  • "Many pacemaker candidates may not be aware of leadless pacing, or even realize they have different treatment options," said Andrea Baer, Executive Director, Mended Hearts.
  • "We are excited to partner with Mended Hearts to help educate patients about their pacing options."
  • Mended Hearts improves quality of life for heart patients and their families through ongoing peer-to-peer support, education and advocacy.